Leidos Holdings IncDHA plans to replace Leidos as lead integrator on MHS GENESIS, causing analyst downgrades on profit margin and growth concerns.

The Defense Health Agency intends to replace Leidos Holdings as the lead systems integrator for the MHS GENESIS electronic health record program, a multi-year rollout across U.S. military treatment facilities. The decision introduces uncertainty for Leidos' health segment and its position in the federal health IT market, with analysts issuing downgrades citing concerns about profit margins and organic growth. The shift comes as government agencies re-examine vendor concentration in complex technology programs, and the scope of any remaining work, timing of changes, and management's response will be key issues for shareholders. Leidos stock has fallen 8.2% over the past 30 days, trading at US$113.58, roughly 38% below the average analyst target of about US$183.27.
Leidos Holdings IncDHA plans to replace Leidos as lead integrator on MHS GENESIS, causing analyst downgrades on profit margin and growth concerns.